Immunological Effects of Sublingual Immunotherapy: Clinical Efficacy Is Associated with Modulation of Programmed Cell Death Ligand 1, IL-10, and IgG4
Open Access
- 15 December 2010
- journal article
- clinical trial
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 185 (12) , 7723-7730
Abstract
Sublingual immunotherapy (SLIT) is an alternate route of administration of allergen-specific immunotherapy with an improved safety profile; to clarify the immune mechanisms elicited by this therapy, we analyzed the clinical and immunologic effects of SLIT in patients with a clinical history of ragweed sensitization. To analyze possible difference among immunotherapeutic protocols, we also compared patients receiving preseasonal, seasonal, or prolonged sublingual therapy (≥3 y); patients receiving symptomatic therapy alone were enrolled as well in the study. Clinical and immunological parameters were measured twice in and out of the pollination period. Clinical benefits, as measured by the visual analog scale for symptoms and for use of drugs, were evident in all three groups of individuals receiving immunotherapy, but were significantly better in patients undergoing prolonged SLIT. Immunologically, SLIT resulted in increased IL-10 production, programmed cell death ligand 1 expression, and concentration of allergen-specific IgG4, as well as in the reduction of CD80 and CD86 expression and IL-4 production. SLIT, thus, is associated with modulation of programmed cell death ligand 1 expression and IL-10 synthesis and favors the production of allergen-specific IgG4. These effects are evident from the first pollen season, independently from therapeutic regimen (preseasonal or seasonal) even if a prolonged treatment is necessary to obtain full clinical efficacy. A more detailed understanding of the interaction of allergen and APCs within the oral mucosa will allow improved targeting of allergy vaccine.Keywords
This publication has 56 references indexed in Scilit:
- Tolerance induction after specific immunotherapy with pollen allergoids adjuvanted by monophosphoryl lipid A in childrenClinical and Experimental Immunology, 2010
- PD-L1 regulates the development, maintenance, and function of induced regulatory T cellsJournal of Experimental Medicine, 2009
- Efficacy of grass pollen sublingual immunotherapy for three consecutive seasons and after cessation of treatment: the ECRIT studyAllergy, 2009
- Administration regimens for sublingual immunotherapy to pollen allergens: What do we know?Allergy, 2009
- IL-10 and PD-L1 operate through distinct pathways to suppress T-cell activity during persistent viral infectionProceedings of the National Academy of Sciences, 2008
- Programmed death 1 ligand signaling regulates the generation of adaptive Foxp3 + CD4 + regulatory T cellsProceedings of the National Academy of Sciences, 2008
- Original article: Visual analog scales can assess the severity of rhinitis graded according to ARIA guidelinesAllergy, 2007
- Immunological mechanisms of sublingual immunotherapyAllergy, 2006
- Potential role of interleukin-10-secreting regulatory T cells in allergy and asthmaNature Reviews Immunology, 2005
- IL‐10 and TGF‐β cooperate in the regulatory T cell response to mucosal allergens in normal immunity and specific immunotherapyEuropean Journal of Immunology, 2003